What Do We Know about Candida auris? State of the Art, Knowledge Gaps, and Future Directions.
Victor Garcia-BustosMarta D Cabanero-NavalonAmparo Ruiz-SauríAlba Cecilia Ruiz-GaitánMiguel SalavertMaría Ángeles Tormo-MasJavier PemánPublished in: Microorganisms (2021)
Candida auris has unprecedently emerged as a multidrug resistant fungal pathogen, considered a serious global threat due to its potential to cause nosocomial outbreaks and deep-seated infections with staggering transmissibility and mortality, that has put health authorities and institutions worldwide in check for more than a decade now. Due to its unique features not observed in other yeasts, it has been categorised as an urgent threat by the Centers for Disease Control and Prevention and other international agencies. Moreover, epidemiological alerts have been released in view of the increase of healthcare-associated C. auris outbreaks in the context of the COVID-19 pandemic. This review summarises the current evidence on C. auris since its first description, from virulence to treatment and outbreak control, and highlights the knowledge gaps and future directions for research efforts.
Keyphrases
- healthcare
- candida albicans
- multidrug resistant
- biofilm formation
- acinetobacter baumannii
- pseudomonas aeruginosa
- public health
- current status
- staphylococcus aureus
- cardiovascular events
- klebsiella pneumoniae
- mental health
- drug resistant
- health information
- cardiovascular disease
- risk factors
- social media
- antimicrobial resistance
- cystic fibrosis
- risk assessment
- combination therapy
- saccharomyces cerevisiae
- quality improvement
- coronary artery disease
- health insurance
- cell wall